Li Kang Biomedical Co Forward P/E
The Forward P/E Ratio of Li Kang Biomedical Co (6242.TWO) as of Oct 11, 2026 is 14.53. In the previous year, Forward P/E Ratio was 15.82 — a change of -8.11% (lower).
Get this data via API
Financial Data API
Forward P/E
14.53
YoY
-8.11%
Last updated:
The Li Kang Biomedical Co Forward P/E history
3 Years
10 Years
25 Years
Max
| YEAR | Forward P/E | YoY |
|---|---|---|
| 14.53 | -8.11% | |
| 15.82 | +44.10% | |
| 10.98 | +0.99% | |
| 10.87 | -54.11% | |
| 23.68 | +34.67% | |
| 17.59 | +3.97% | |
| 16.92 | +6.56% | |
| 15.87 | +74.28% | |
| 9.11 | -54.01% | |
| 19.80 | -14.08% | |
| 23.05 | — |
Li Kang Biomedical Co Stock analysis
Frequently Asked Questions about Li Kang Biomedical Co stock
Forward P/E Ratio of Li Kang Biomedical Co is 14.53 in 2025.
Forward P/E Ratio of Li Kang Biomedical Co changed from 15.82 to 14.53, representing a -8.11% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Forward P/E Ratio Li Kang Biomedical Co since 2006 – with annual values, charts, and detailed analysis.
The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.
To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Li Kang Biomedical Co with sector peers and the industry average to assess whether it is attractive.
Valuation — Li Kang Biomedical Co
All Key Metrics — Li Kang Biomedical Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth